Che cos'è a fisiopatologia del cancro ała prostata?
Ła patofisiologia del cancro de prostata ła se riferise ai mecanismi e ai processi che porta al sviłupo e ała progression deła małatia.
El cancro deła prostata xe un tumore maligno che vien fora dałe cellule deła prostata, che xe un organo picenin a forma de noxe che se cata soto ała vescica nei omeni.
Ła prostata ła produxe fluido seminale, che el nutre e el trasporta el sperma.
Ła causa esata del cancro ała prostata no ła xe conpletamente capìa, ma se sa che diversi fatori i aumenta el riscio de sviłupar ła małatia.
Questi include età, storia familiare, razza e serte mutassioni genetiche.
El cancro deła prostata xe pì comun nei omeni pì veci, co ła majoransa dei casi che se verifica nei omeni de pì de 65 anni.
Inoltre, i òmeni co na storia familiare de cancro ała prostata i xe a riscio aumentà, come i òmeni afroamericani e i òmeni de origine caraibica.
Ła patofisiologia del cancro deła prostata ła coinvolge ła crésita e divixion incontrolà dełe sèłułe drento deła prostata.
Questo pol suceder a causa de mutassiòn genetiche che porta ała sovraespression de serti fatori de cresita o ała inatività dei geni sopressori de tumori.
Ste mutassiòn pol portar a na cressita non regołada dełe cellule, portando ała formasión de un tumore.
Co el tumore crese, el pol invadar tessudi e organi visini, come vescica, retto e linfonodi visini.
In serti casi, łe celule cancerose łe se pol stacar dal tumore primario e sparpagnarse in altre parti del corpo atraverso el sangue o el sistema linfàtico, un processo conosùo come metastasi.
Na volta che el cancro se ga difondesto, pol essar pì difisiłe curarlo.
El cancro deła prostata pol anca esar influensà da fatori ormonali, in particołar da l'ormone androgeno testosterone.
El testosterone pol stimołar a cressita dełe cellule del cancro deła prostata e tanti trati pa'l cancro deła prostata i mira a ridur i livełi de sto ormone o blocar i so efeti.
In sintesi, a fisiopatologia del cancro de prostata coinvolge a cressita e a division incontrolà dełe cellule drento ała prostata, che pol esar influensà da fatori genetici, ormonali e ambientałi.
Capìr i mecanismi fondamentałi dea malatia xe fondamentałe pa sviłupar cure efficaci e migliorar i risultati pa i pasienti col cancro dea prostata.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Disclaimer: medego']
['Sto sito web el xe fornìo solo par scopi educativi e informativi e no el costituise un consejo mèdego o servisi profesionali.']
['Łe informasion fornìe no łe ga da esar usà pa diagnosticar o curar un problema de salute o na malatia, e chi che serca un consijo mèdego personal el ga da consultar un mèdego licensià.']
['Te prego de notare che a rete neurałe che ła genera risposte ałe domande, ła xe particołarmente imprecisa quando se trata de contenuti numèrici, par exenpio el nùmaro de persone a cui xe stà diagnosticà na determinada małatia.']
['Serca senpre el consijo del to dotor o de un altro fornitor de sałute cualificà riguardo a na condision mèdega. Mai trascurar el consijo mèdego profesionałe o ritardarlo nel sercarlo par via de calcossa che te ghè leto su sto sito. Se te pensi de aver na emergensa mèdega, ciama el 911 o va al pronto socorso pì visin imediatamente.']
['Disclaimer: copyright']
['El Digital Millennium Copyright Act del 1998, 17 U.S.C. § 512 (el DMCA) el dà ricorso ai proprietari de copyright che i crede che el material che vien fora su Internet infranga i so diriti soto ła lege sui copyright dei Stati Uniti. ']
["Se te credi in bona fede che un contenuto o un material messo a dispoxision in conesion col nostro sito o i nostri servisi infranga i to diriti de autor, ti (o el to agente) te pol mandarne na notisia domandando che el contenuto o el material sia rimoso, o che l'acesso sia blocà."]
['I avixi i ga da esare mandà par scrito via e-mail (varda ła sezion "Contato" pa\'l indiriso e-mail).']
["El DMCA richiede che a to notisia de presunta violasion de copyright includa e seguenti informasion: (1) descrixion del lavoro proteto da copyright che xe l'ogeto de ła presunta violasion; (2) descrixion del presunto contenuto che viola e informasion sufisente par permeterne a noi de localixar el contenuto; (3) informasion de contato, incluxo el to indirizo, numero de telefono e indirizo email; (4) na dichiarasion da parte tua che te credi in bona fede che el contenuto nel modo reclamà no xe autorizà dal proprietario del copyright, o dal so agente, o da l'operasion de nisuna lege; "]
["(5) 'na to dichiarasion, firmada soto pena de spergiuro, che łe informasion neła notìfega xe precise e che te ghè l'autorità de far valer i diriti de autor che i xe stai violadi;"]
['e (6) na firma fisica o ełetrònica del titołare del copyright o de na persona autorizada a agire a nome del titołare del copyright. ']
['Se no te meti tute łe informasion sora łe pol far in modo che el tratamento del to reclamo el se intardi.']
['Contato']
['Ve prego de mandarne na mail co qualsiasi domanda/suggerimento.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Circa']
['BioMedLib usa computer automatici (algoritmi de machine-learning) pa generar coppie de domande e risposte.']
['Cominsiemo co 35 milioni de publicassioni biomediche de PubMed/Medline. e anca pagine web de RefinedWeb.']
